Ivonescimab with chemo for early-stage triple negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new drug, ivonescimab, combined with standard chemotherapy before surgery for people with high-risk early-stage triple negative breast cancer. The goal is to see if adding this drug improves treatment response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have early-stage triple negative breast cancer (ER and PR less than 10%, HER2 negative) that is high-risk.
- Your tumor is at least 1 centimeter or has spread to nearby lymph nodes.
- You are planning to receive chemotherapy and an immune checkpoint inhibitor before surgery as standard care.
- Your overall health is good (able to do most daily activities) and your organ function is adequate.
- You are not pregnant or breastfeeding, and you agree to use effective contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the drug ivonescimab to standard chemotherapy before surgery can improve outcomes for people with triple-negative breast cancer. The treatment is given before surgery to shrink the tumor and make surgery more effective.
This trial tests whether adding an immunotherapy drug called toripalimab to standard chemotherapy, before surgery, can improve treatment for early triple-negative breast cancer. It compares two chemotherapy approaches—one with anthracyclines and one without—to see which works better when combined with toripalimab.
This study tests whether adding an immune therapy (a PD-1 antibody) plus a blood-vessel–blocking treatment to standard chemo improves outcomes for people with surgically treated triple-negative breast cancer. Everyone gets chemotherapy, but some will also get the added drugs to try to reduce cancer coming back.
This trial tests whether adding sintilimab (an immunotherapy) and bevacizumab (a drug that blocks blood supply to tumors) to standard chemotherapy before surgery can improve outcomes for women with stage II or III triple-negative breast cancer. It may help your immune system fight the cancer more effectively.
This trial tests whether adding an experimental drug called INBRX-106 to the standard immunotherapy (pembrolizumab) and chemotherapy before surgery can improve outcomes for patients with early-stage triple-negative breast cancer. The goal is to shrink the tumor and potentially reduce the risk of the cancer coming back.
This trial tests whether giving pembrolizumab (an immunotherapy drug) together with chemotherapy before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by shrinking the tumor before removal.
Hear when a new Early Stage Triple-Negative Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.